Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8742080 | 1.00 | HSD17B10 (0.62) | HSD17B10GLASMN1; SMN2SLC6A9CYP1A2 | |
| SCHEMBL6848102 | 0.91 | HSD17B10 (0.64) | HSD17B10SMN1; SMN2SLC6A9CYP1A2MAPK1 | |
| SCHEMBL3503521 | 0.91 | HSD17B10 (0.64) | HSD17B10SMN1; SMN2SLC6A9CYP1A2MAPK1 | |
| SCHEMBL6744121 | 0.91 | HSD17B10 (0.64) | HSD17B10SMN1; SMN2SLC6A9CYP1A2MAPK1 | |
| Tetraxetan SCHEMBL2635294 | 0.91 | HSD17B10 (0.64) | HSD17B10SMN1; SMN2SLC6A9CYP1A2MAPK1 | |
| Tetraxetan SCHEMBL18018 | 0.91 | HSD17B10 (0.64) | HSD17B10SMN1; SMN2SLC6A9CYP1A2MAPK1 | |
| SCHEMBL321989 | 0.91 | HSD17B10 (0.64) | HSD17B10SMN1; SMN2SLC6A9CYP1A2MAPK1 | |
| Tetraxetan SCHEMBL2017956 | 0.91 | HSD17B10 (0.64) | HSD17B10SMN1; SMN2SLC6A9CYP1A2MAPK1 | |
| SCHEMBL173508 | 0.91 | HSD17B10 (0.64) | HSD17B10SMN1; SMN2SLC6A9CYP1A2MAPK1 | |
| SCHEMBL3660521 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577371-B2 | Oxidatively curable coating composition | MILLIKEN INDUSTRIALS LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| EP-4308550-A1 | CHIRAL TACN/NOTA COMPOUNDS/DERIVATIVES WITH AND WITHOUT METALS FOR APPLICATION | The Hong Kong Polytechnic University (CN) | 2024-01-24 | — | — | EP | disclosed |
| EP-3818115-B1 | OXIDATIVELY CURABLE COATING COMPOSITION | MILLIKEN INDUSTRIALS LTD (GB) | 2023-11-22 | — | — | EP | disclosed |
| CN-117043145-A | Metal-containing and metal-free chiral TACN/NOTA compounds/derivatives for administration | 香港理工大学 | 2023-11-10 | — | — | CN | disclosed |
| WO-2022194298-A1 | Chiral TACN/NOTA compounds/derivatives with and without metals for application | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-09-22 | — | — | WO | disclosed |
| US-20210221975-A1 | OXIDATIVELY CURABLE COATING COMPOSITION | Borchers Catalyst (UK) Limited (GB) | 2021-07-22 | — | — | US | disclosed |
| CN-112752810-A | Oxidatively curable coating composition | 博奇斯催化剂(英国)有限公司 | 2021-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577371-B2 | Oxidatively curable coating composition | TET1, JMJD6, SETDB1 | HSD17B10 1791/4885GLA 2046/4885SMN1; SMN2 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.